Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Biosimilars Advisory Service : Global Biosimilars Markets – Regulations, Pipelines, and Major Players | G7 | 2015
Latest update: Global Biosimilars Pipeline updated on 31 July 2015 The biosimilars market is not all about the United States, Europe, and Japan. Although these developed markets account for 75%…
Gram-Negative Infections due to Carbapenem-Resistant Organisms | Decision Base | US | 2015
The Alarming Scarcity of Treatment Options for These Pathogens Presents an Attractive Market Opportunity for Novel Antibiotics The carbapenems are a class of potent gram-negative antibiotics…
Multiple Sclerosis | Emerging Therapies | Lemtrada (alemtuzumab) | US | Wave 1 | 2015
LaunchTrends®: Lemtrada (US) is a four-wave syndicated report series that specifically tracks the introduction of Lemtrada, a potent, intravenous disease-modifying therapy (DMT) approved for the…
Novel Oral Anticoagulants for Acute Coronary Syndrome, Atrial Fibrillation, and Venous Thromboembolism in the EU5 | Physician & Payer Forum | EU5 | 2015
How Are Payer Policies and Physician Preferences Shaping the Prescribing Landscape? The European oral anticoagulation market has undergone a dramatic expansion in the treatment armamentarium in…
Special Report: How Are Novel Follow-On Therapies Impacting Multiple Sclerosis Treatment Paradigms in the United States?
Special Report: How Are Novel Follow-On Therapies Impacting Multiple Sclerosis Treatment Paradigms in the United States? is designed to assess and quantify the market impact of the 2014 launches of…
Asthma (Moderate to Severe) – How Can Novel Biologics Targeting Niche Populations Maximize Uptake in an Increasingly Competitive Marketplace? | Decision Base | US/EU5 | 2015
How Can Novel Biologics Targeting Niche Populations Maximize Uptake in an Increasingly Competitive Marketplace? Although several effective anti-inflammatory agents and bronchodilators are…
Alzheimer’s Disease (Mild to Moderate) – Amid Substantial Unmet Need, What Clinical Improvements Do Neurologists and Payers Expect of Novel Symptomatic and First-to-Market Disease-Modifying Therapies? | Decision Base | US/EU5 | 2015
Amid Substantial Unmet Need, What Clinical Improvements Do Neurologists and Payers Expect of Novel Symptomatic and First-to-Market Disease-Modifying Therapies? Alzheimer’s disease (AD) will…
